Welcome to our dedicated page for Charles Riv Labs Intl SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Charles River Laboratories International, Inc. filings document the company’s operating results, material events, governance matters, and capital-structure disclosures as a New York Stock Exchange-listed issuer with common stock trading under CRL. Form 8-K reports cover quarterly and annual financial results, guidance, share repurchase activity, completed portfolio changes, conference disclosures, and executive appointment and compensation matters.
Proxy materials describe shareholder voting matters, board elections, executive compensation, equity incentive plans, and auditor ratification. The filing record also reflects disclosure categories tied to the company’s drug discovery and development services, including segment performance for Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions, along with forward-looking risk language and compliance matters.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. director Reshema Kemps-Polanco reported receiving equity awards in the form of restricted stock units covering a total of 1,973 shares of Common Stock on May 8, 2026, valued at $177.62 per share.
The Form 4 shows one award for 535 shares and another for 1,438 shares, both characterized as grants or awards rather than open-market purchases. According to the footnotes, these unvested restricted stock units vest upon the earlier of May 8, 2027 or the business day prior to the company’s next annual meeting of shareholders.
One of the grants was made in lieu of director service fees for the term commencing May 5, 2026, meaning part of the director’s compensation is being paid in equity instead of cash. These are routine compensation-related acquisitions and not market trades.
Charles River Laboratories International director Virginia M. Wilson received an equity award. On 5/8/2026 she was granted 1,438 shares of Common Stock, valued at $177.62 per share, as a grant or award. After this acquisition, she directly holds 6,349 shares. According to the disclosure, these unvested restricted stock units will vest on the earlier of 5/8/2027 or the business day before the company’s next annual meeting of shareholders.
FOSTER JAMES C reported acquisition or exercise transactions in this Form 4 filing.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. director James C. Foster reported equity awards in the form of common stock tied to restricted stock units. On May 8, 2026, he received awards covering 422 shares and 1,438 shares of common stock at $177.62 per share.
These awards were granted in lieu of director service fees for the term commencing May 5, 2026. The unvested restricted stock units vest on the earlier of May 8, 2027 or the business day prior to the company’s next annual meeting of shareholders.
Following one of the reported awards, Foster is shown as directly holding 281,553 shares of common stock. Additional indirect holdings are reported through his spouse and various trusts, including GRAT structures, indicating a mix of direct and indirect ownership interests.
Charles River Laboratories reported first-quarter 2026 revenue of $995.8 million, up 1.2% from a year earlier, but revenue declined 1.5% on an organic basis once currency and divestitures are excluded. GAAP results swung to a net loss of $14.8 million, or $(0.30) per share, mainly due to a $118.0 million loss on assets held for sale tied to the CDMO and Cell Solutions divestiture.
On a non-GAAP basis, operating margin fell to 16.3% from 19.1%, and net income decreased 14.6% to $101.7 million, or $2.06 per diluted share, versus $2.34 a year ago, largely from higher DSA study costs, unfavorable RMS mix, and higher stock-based compensation. Segment performance was mixed, with Manufacturing organic revenue up 2.9% and RMS and DSA down 5.5% and 1.4%, respectively.
The company completed the sale of its CDMO and Cell Solutions businesses on May 6, 2026, and expects to sell certain European Discovery Services sites in May 2026 to sharpen focus on core drug development testing. It also repurchased 1.1 million shares for $200 million, leaving $800 million under its $1.0 billion authorization. Management reaffirmed 2026 organic revenue and non-GAAP EPS guidance of $10.80–$11.30, while trimming reported revenue growth by about 50 basis points for foreign exchange and updating GAAP EPS guidance to $5.35–$5.85.
Charles River Laboratories International Inc ownership disclosure: Invesco Ltd. reports beneficial ownership of 2,397,252 shares of Common Stock, representing 4.9% of the class. The filing states Invesco Ltd. has sole voting power over 2,387,914 shares and sole dispositive power over 2,397,252 shares; the shares are held of record by clients of Invesco Ltd.
FMR LLC reported beneficial ownership of 3,456,244.72 shares of Charles River Labs International common stock, representing 7.0% of the class as of 03/31/2026. The filing shows sole dispositive power of 3,456,244.72 shares and sole voting power of 3,423,033.36 shares held by FMR LLC.
The Schedule 13G names Abigail P. Johnson as having sole dispositive power for 3,456,244.72 shares. The filing is signed under a power of attorney and references Exhibit 99 and a 13d-1(k)(1) agreement.
Coleman Glenn reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories International EVP & Chief Financial Officer Glenn Coleman received an equity grant of 21,112 shares of Common Stock on May 1, 2026. The grant was reported at $165.78 per share, and following this award he directly owns 21,112 shares.
According to the filing footnote, these unvested restricted stock units are scheduled to vest in equal annual installments on May 1, 2027, May 1, 2028, May 1, 2029, and May 1, 2030, tying the award to multi‑year service and performance with the company.
Charles River Laboratories International Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 3,634,376 shares of Common Stock, representing 7.38% of the class as of 03/31/2026. The filing shows sole voting power for 432,172 shares and sole dispositive power for 3,634,376 shares. The filing is signed on 04/29/2026 by Ashley Grim, Head of Global Fund Administration.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. executive Glenn Coleman, the company’s EVP & Chief Financial Officer, filed an initial Form 3 reporting his beneficial ownership of the company’s Common Stock. The filing shows he holds 0 shares directly following the reported holding entry dated April 6, 2026.
Form 3 filings introduce insiders’ starting ownership positions to the market, providing a baseline for any future Form 4 reports of purchases, sales, or equity awards.